A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.

Inclusion criteria

• Age 18-75 years old, male or female;
• The patient volunteered to participate in the study, and he or his legal guardian signed the Informed Consent;
• Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014);
• Patients with a clear diagnosis of relapsed or refractory multiple myeloma；
• The patient have one or more measurable multiple myeloma lesion, must include one of the following conditions:

• Serum M protein≥1.0 g/dL(10g/L)
• Urine M protein≥200 mg/24h
• Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥10mg / dL
• Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination;
• ECOG scores 0 - 1;
• Echocardiography showed normal diastolic function, left ventricular ejection fraction (LVEF) ≥50%, and no severe arrhythmia;
• No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.
• Absolute neutrophil count ≥1.0 × 109 / L, platelet count ≥50 × 109 / L; total serum bilirubin ≤1.5mg / dl; serum ALT or AST less than 2.5 times the upper limit of normal; serum creatinine ≤2.0mg / dl;
• No contraindications of peripheral blood apheresis;
• Expected survival time > 12 weeks;.
• Female subjects of childbearing age must have a negative urine / blood pregnancy test within 7 days before cell therapy and not be in lactation; female or male subjects of childbearing age need to take effective contraception throughout the study.

Exclusion criteria

• Have a history of allergy to cellular products;
• Presence of clinically significant cardiovascular disease;
• A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral ischemia or hemorrhagic disease;
• Need to use any anticoagulant (except aspirin);
• Patients requiring urgent treatment due to tumor progression or spinal cord compression;
• Patients with CNS metastasis or symptoms of CNS involvement;
• After allogeneic hematopoietic stem cell transplantation;
• Plasma cell leukemia;
• Received systemic anti-tumor treatment within 2 weeks before apheresis, and within 1 week before apheresis, prednisone (or equivalent amount of other corticosteroids) was applied in excess of 5 mg/d ;
• Patients with autoimmune diseases, immunodeficiency, or other immunosuppressive agents;
• Uncontrolled active infection;
• Have used any CAR T cell products or other genetically modified T cell therapy before;
• Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV infected persons;
• Have a history of alcoholism, drug addiction and mental illness;
• Participated in any other clinical trial within 1 months;
• The investigators believe that there are other circumstances that are not suitable for the trial.